B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases
Authors:
- Shirish R. SangleSSShirish R. Sangle
- Pamela M.K. LutaloPLPamela M.K. Lutalo
- Rachel J. DaviesRDRachel J. Davies
- Munther A. KhamashtaMKMunther A. Khamashta
- David P. D'CRuzDDDavid P. D'CRuz
- 1 June 2013
- journal article
- case report
- Published by Elsevier in Journal of Autoimmunity
- Vol. 43, 55-59
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals of the Rheumatic Diseases, 2012
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011Annals of the Rheumatic Diseases, 2012
- Treatment with biologics of pregnant patients with rheumatic diseasesCurrent Opinion in Rheumatology, 2011
- Safety of rituximab therapy during twins' pregnancyRheumatology, 2010
- A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus NephritisClinical Journal of the American Society of Nephrology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximabMultiple Sclerosis Journal, 2009
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell DevelopmentJournal of Immunology Research, 2008
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Treatment of Lupus NephritisDrugs, 2003